Form 4: Inhibikase Therapeutics Director Reports Option Repricing and Acquisition of Derivative Securities

Director Dennis N. Berman reports adjustments to stock options and acquisition of derivative securities in Inhibikase Therapeutics, Inc. following a reverse stock split and option repricing.

Summary

• Dennis N. Berman, a director of Inhibikase Therapeutics, Inc. [IKT], filed a Form 4 detailing changes in beneficial ownership.
• The report covers transactions effective January 21, 2025, including an option repricing approved by the board on October 9, 2024, and stockholders on January 3, 2025.
• The transactions involve adjustments to stock options due to a one-for-six reverse stock split on June 30, 2023.
• Berman acquired and disposed of various stock options with exercise prices ranging from $1.26 to $60.
• Some options are held directly, while others are held indirectly through Molino Ventures, LLC.
• The options have various expiration dates, extending to July 16, 2031.
• The repricing did not change any other terms of the options.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock option repricing and adjustments, with no inherent positive or negative sentiment.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• Shareholders are informed about changes in insider ownership and stock option adjustments.

Key Dates